BMS Resets 2023 Guidance With Bigger Than Expected Drop In Revlimid Sales

Pressure On New Drugs As Long-Term Guide Maintained

 
• By Mandy Jackson
  
Big red button on a gray wall
BMS hit the reset button on its 2023 revenue and Revlimid guidance • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business